1 / 4

Stomach Cancer Drugs Market Research Report to Design a Cohesive and Predictive Business Strategy 2026

Stomach cancer is the fifth most common cancer globally regardless of gender as reported by the World Cancer Research Fund (WCRF) in 2018.<br>

rushi12
Télécharger la présentation

Stomach Cancer Drugs Market Research Report to Design a Cohesive and Predictive Business Strategy 2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stomach Cancer Drugs Market - Size, Share, Stomach Cancer Drugs Market - Size, Share, Growth, Outlook, and Opportunity Analysis, Growth, Outlook, and Opportunity Analysis, 2018-2026 2018-2026 Stomach cancer is the fifth most common cancer globally regardless of gender as reported by the World Cancer Research Fund (WCRF) in 2018. There are many factors which cause stomach cancer such as unhealthy diet, smoking, obesity, alcohol, and Helicobacter pylori infection. According to the Cancer Research U.K. data of 2016, one out of three stomach cancer cases is related to Helicobacter pylori infection in the U.K. annually. Stomach cancer tests identify the stage of the cancer and the patient is treated accordingly. Targeted drug therapies are frequently used to treat stomach cancer as these drugs target the rapidly dividing cells and have less side effects. Drugs that target HER2 are under developmental studies to treat advanced stomach cancer. For instance, pertuzumab in combination with trastuzumab and chemotherapy is under phase 3 clinical trials to treat metastatic gastroesophageal junction or gastric cancer. Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2667 Stomach cancer, is a buildup of abnormal cells that form a mass in part of the stomach. Symptoms of stomach cancer include fatigue, feeling bloated after eating, severe heartburn, severe indigestion, persistent nausea, stomach pain, persistent vomiting, and unintentional weight loss. There are many treatments available for stomach cancer such as targeted drug therapy, chemotherapy, immunotherapy etc. Stomach cancer drugs are also used in combinations to increase their effectiveness to fight stomach cancer. For instance, TPF is a combination of drugs which include Docetaxel (Taxotere), Cisplatin (Platinol), and Fluorouracil, which is used to kill cancer cells in different ways. Increasing FDA approvals of biosimilars for treatment of stomach cancer is expected to drive growth of the stomach cancer drugs market

  2. The stomach cancer drugs market revenue is expected to increase, owing to increasing number of FDA approvals for biosimilars. Adoption of biosimilars in last five years is on a high demand because of the comparatively lower price than biologics treatment of stomach cancer. For instance, in 2017 Biocon Ltd., in partnership with Mylan N.V., received FDA approval for Ogivri (trastuzumab) for the treatment of stomach cancer or gastro-esophageal junction adenocarcinoma. Ogivri is the first FDA-approved biosimilar of Herceptin and the first biosimilar from Mylan and Biocon’s joint portfolio approved in the U.S. Further, In March 2019, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) approval of TRAZIMERA (trastuzumab), a biosimilar of Herceptin (trastuzumab), for the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Report includes chapters which deeply display the following deliverable about industry : • Stomach Cancer Drugs Market Research Objective and Assumption • Stomach Cancer Drugs Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Stomach Cancer Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Stomach Cancer Drugs Market, By Regions • Stomach Cancer Drugs Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Stomach Cancer Drugs Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Stomach Cancer Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Stomach Cancer Drugs Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Stomach Cancer Drugs Market - Competitive Landscape Key players operating in the global stomach cancer drugs market include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd., Daiichi

  3. Sankyo Co. Ltd., Merck KGaA, AstraZeneca Plc, Otsuka Holdings Co. Ltd., Sanofi S.A., and F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb (BMS), Jiangsu HengRui Medicine Co. Ltd., Gilead Science Inc., Celgene Corporation, Taiho Pharmaceutical, Boston Biomedical Inc., and Merck & Co. Inquire Here Before Purchase: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2667 Detailed Segmentation: Global Stomach Cancer Drugs Market, By Therapy Type: • Kinase Inhibitors • Nucleoside Metabolic Inhibitors • Anthracyclines • Microtubule Inhibitors • VEGF Antibodies • HER2 Receptor Antagonists • Car T Cell Therapy Global Stomach Cancer Drugs Market, By Application: • Adenocarcinomas • Gastrointestinal Stromal Tumors • Carcinoid Tumors Global Stomach cancer drugs Market, By Distribution Channel: • Hospital Pharmacy • Retail Pharmacy • Online Pharmacy Global Stomach cancer drugs Market, By Region: • North America • • • • About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us

  4. Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

More Related